Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Fenger, Joelle M ^a   Bear, Misty D ^a   Volinia, Stefano ^b   Lin, Tzu Yin ^c   Harrington, Bonnie K ^a   London, Cheryl A ^a   Kisseberth, William C ^a  

^a Department of Veterinary Clinical Sciences ^*  (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mast cell; microRNA; miR 9

Indexed keywords

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAST CELLS; MICE; MICE, INBRED C57BL; MICRORNAS; NEOPLASM INVASIVENESS;

EID: 84893672636     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-84     Document Type: Article

References (52)

1. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007, 27(2):121-132.
2. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 2003, 33(3):473-489. 10.1016/S0195-5616(03)00003-2, 12852232.
3. Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46(1):35-48. 10.1080/10428190400010775, 15621779.
4. Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, KITamura Y, Kanakura Y. Ligand-independent activation of c-KIT receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994, 83(9):2619-2626.
5. Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, KITamura Y, Kanakura Y. Substitution of an aspartic acid results in constitutive activation of c-KIT receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995, 106(4):377-385. 10.1159/000236870, 7536501.
6. Downing S, Chien MB, Kass PH, Moore PE, London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-KIT in mast cell tumors of dogs. Am J Vet Res 2002, 63(12):1718-1723. 10.2460/ajvr.2002.63.1718, 12492288.
7. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002, 39(5):529-535. 10.1354/vp.39-5-529, 12243462.
8. Letard S, Yang Y, Hanssens K, Palmérini F, Leventhal PS, Guéry S, Moussy A, Kinet JP, Hermine O, Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008, 6(7):1137-1145. 10.1158/1541-7786.MCR-08-0067, 18644978.
9. Lin TY, London CA. A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet Immunol Immunopathol 2006, 114(3-4):320-334.
10. Leibman NF, Lana SE, Hansen RA, Powers BE, Fettman MJ, Withrow SJ, Ogilvie GK. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med 2000, 14(6):583-586. 10.1111/j.1939-1676.2000.tb02280.x, 11110378.
11. Giantin M, Aresu L, Benali S, Aricò A, Morello EM, Martano M, Vascellari M, Castagnaro M, Lopparelli RM, Zancanella V, Granato A, Mutinelli F, Dacasto M. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours. J Comp Pathol 2012, 147(4):419-429. 10.1016/j.jcpa.2012.01.011, 22520817.
12. Schlieben P, Meyer A, Weise C, Bondzio A, Einspanier R, Gruber AD, Klopfleisch R. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. Vet J 2012, 194(2):210-214. 10.1016/j.tvjl.2012.04.002, 22578690.
13. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce C. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12(12):580-587. 10.1016/j.molmed.2006.10.006, 17071139.
14. Monticelli S, Ansel KM, Xiao C, Socci ND, Krichevsky AM, Thai TH, Rajewsky N, Marks DS, Sander C, Rajewsky K, Rao A, Kosik KS. MicroRNA profiling of the murine hematopoietic system. Genome Biol 2005, 6(8):R71. 10.1186/gb-2005-6-8-r71, 1273638, 16086853.
15. Mayoral RJ, Pipkin ME, Pachkov M, van Nimwegen E, Rao A, Monticelli S. MicroRNA-221-222 regulate the cell cycle in mast cells. J Immunol 2009, 182(1):433-445. 2610349, 19109175.
16. Mayoral RJ, Deho L, Rusca N, Bartonicek N, Saini HK, Enright AJ, Monticelli S. MiR-221 influences effector functions and actin cytoskeleton in mast cells. PLoS One 2011, 6(10):e26133. 10.1371/journal.pone.0026133, 3192147, 22022537.
17. Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM. KIT signaling regulates MITF expression through miRNAs in normal and malignant cell proliferation. Blood 2011, 117(13):3629-3640. 10.1182/blood-2010-07-293548, 3072881, 21273305.
18. Lin TY, Rush LJ, London CA. Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol 2006, 113(1-2):37-52.
19. Tsai M, Miyamoto M, Tam SY, Wang ZS, Galli SJ. Detection of mouse mast cell-associated protease mRNA. Heparinase treatment greatly improves RT-PCR of tissues containing mast cell heparin. Am J Pathol 1995, 146(2):335-343. 1869864, 7856746.
20. Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011, 134(Pt 12):3578-3589. 3235556, 22088562.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95(25):14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
23. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 2009, 9:81. 10.1186/1471-2407-9-81, 2666757, 19284568.
24. Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biological activity against malignant mast cell lines via down-regulation of constitutively activated KIT. Blood 2010, 115(21):4217-4225. 10.1182/blood-2009-07-231985, 3398750, 20233974.
25. Thulin P, Wei T, Werngren O, Cheung L, Fisher RM, Grander D, Corocran M, Ehrenborg E. MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response. Int J Mol Med 2013, 31(5):1003-1010. 3658603, 23525285.
26. Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE. MicroRNA expression in canine mammary cancer. Mamm Genome 2008, 19(7-8):561-569.
27. Uhl E, Krimer P, Schliekelman P, Tompkins SM, Suter S. Identification of altered microRNA expression in canine lymphoid cell lines and cases of B- and T-cell lymphomas. Genes Chromosomes Cancer 2011, 50(11):950-967. 10.1002/gcc.20917, 21910161.
28. Gioia G, Mortarino M, Gelain ME, Albonico F, Ciusani E, Forno I, Marconato L, Martini V, Comazzi S. Immunophenotype-related microRNA expression in canine chronic lymphocytic leukemia. Vet Immunol Immunopathol 2011, 142(3-4):228-235.
29. Noguchi S, Mori T, Hoshino Y, Yamada N, Maruo K, Akao Y. MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet Comp Oncol 2013, 11(2):113-123. 10.1002/vco.306, 23638671.
30. Noguchi S, Mori T, Hoshino Y, Yamada N, Nakagawa T, Sasaki N, Akao Y, Maruo K. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci 2012, 74(1):1-8. 10.1292/jvms.11-0264, 21836381.
31. Vinall RL, Kent MS, DeVere White RW. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res 2012, 73(10):1626-1633. 10.2460/ajvr.73.10.1626, 23013190.
32. Wagner S, Willenbrock S, Nolte I, Escobar HM. Comparison of non-coding RNAs in human and canine cancer. Front Genet 2013, 4:46. 3619122, 23579348.
33. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12(3):247-256. 2845545, 20173740.
34. Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T, Ditzel HJ. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 2012, 134(1):207-217. 10.1007/s10549-012-1969-9, 22294488.
35. Wang J, Zhao H, Tang D, Wu J, Yao G, Zhang Q. Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother Radiopharm 2013, 28(4):283-288.
36. Tan HX, Wang Q, Chen LZ, Huang XH, Chen JS, Fu XH, Cao LQ, Chen XL, Li W, Zhang LJ. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cells. Med Oncol 2010, 27(3):654-660. 10.1007/s12032-009-9264-2, 19572217.
37. Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C, Zhao RC. MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol Oncol 2013, 7(5):884-894. 10.1016/j.molonc.2013.04.007, 23684102.
38. Lu MH, Huang CC, Pan MR, Chen HH, Hung WC. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res 2012, 18(23):6416-6425. 10.1158/1078-0432.CCR-12-0832, 23045246.
39. Zhu L, Chen H, Zhou D, Bai R, Zheng S, Ge W. MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol 2012, 29(2):1037-1043. 10.1007/s12032-011-9975-z, 21562850.
40. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008, 7:35. 10.1186/1476-4598-7-35, 2383925, 18442408.
41. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K, Tong Q. MicroRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 2013, 8(1):e55719. 10.1371/journal.pone.0055719, 3561302, 23383271.
42. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 2009, 276(19):5537-5546.
43. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer 2011, 129(11):2611-2620. 10.1002/ijc.25923, 21225631.
44. Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 2013, 13(1):46-57. 3773942, 23237964.
45. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon y Cajal S, Carnero A. MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis 2007, 28(8):1646-1652. 10.1093/carcin/bgm083, 17426052.
46. Carnero A. MAP17, a ROS-dependent oncogene. Front Oncol 2012, 2:112. 10.3389/fonc.2012.00112, 3434504, 22973555.
47. Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Carnero A, Ramon y Cajal S. MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis 2007, 28(10):2096-2104. 10.1093/carcin/bgm124, 17548903.
48. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007, 217:141-154. 10.1111/j.1600-065X.2007.00509.x, 2275918, 17498057.
49. He SH, Chen P, Chen HQ. Modulation of enzymatic activity of human mast cell tryptase and chymase by protease inhibitors. Acta Pharmacol Sin 2003, 24(9):923-929.
50. Bashkin P, Razin E, Eldor A, Vlodavsky I. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood 1990, 75(11):2204-2212.
51. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev 2011, 30:253-268. 10.1007/s10555-011-9288-x, 21308479.
52. Hunter KE, Palermo C, Kester JC, Simpson K, Li J-P, Tang LH, Klimstra DS, Vlodavsky I, Joyce JA. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene 2013, 1-10. doi:10.1038/onc.2013.142.